Posted by Michael Wonder on 20 Dec 2023
Chiesi Global Rare Diseases receives FDA approval for Filzuvez (birch triterpenes) topical gel for the treatment of epidermolysis bullosa
19 December 2023 - Filzuvez was well tolerated and met the primary outcome with statistical significance, with 41.3% of patients achieving first complete target wound closure within 45 days in the Phase 3 clinical trial.
Chiesi Global Rare Diseases announced today that the US FDA approved Filsuvez (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and older with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa.
